Jun 22,2026
Two New Drug Varieties (Three Specifications) of SSY Group Obtain Approval
On June 22, two new pharmaceutical varieties with three specifications independently developed by SSY Group obtained production registration approvals issued by the National Medical Products Administration (NMPA), and were deemed to have passed the Consistency Evaluation of Quality and Efficacy of Generic Drugs.
Jun 16,2026
SSY Group Shines at CPHI China 2026 – the 24th World Pharmaceutical Raw Materials Exhibition
Gathering global pharmaceutical strengths to jointly unlock new industrial growth opportunities. Held from June 16 to 18 at Shanghai New International Expo Centre, CPHI China 2026 (the 24th World Pharmaceutical Raw Materials Exhibition) welcomed a grand opening.
Jun 15,2026
Cefpodoxime Proxetil Dry Suspension (50mg) of SSY Group Granted Approval
On June 15, the Class 3 chemical drug Cefpodoxime Proxetil Dry Suspension (50mg) independently developed by SSY Group obtained the production registration approval issued by the National Medical Products Administration (NMPA)
Jun 10,2026
SSY Group Debuts at 2026 South Africa International Food & Food Processing Exhibition
Local time June 10, the 2026 South Africa International Food & Food Processing Exhibition grandly opened at Cape Town International Convention Centre. The international trade team of SSY Group attended the show with bulk and specialty raw material products to actively explore the African market.
Jun 08,2026
SSY Group Obtains Registration Approvals for Ceftizoxime Sodium for Injection (1.0g & 0.5g)
On June 8, SSY Group obtained registration approval documents for two specifications of Ceftizoxime Sodium for Injection (1.0g and 0.5g). Since the start of this year, the Group has secured 44 new product approvals, including 33 for finished preparations and 11 for APIs.
Jun 04,2026
Shijiazhuang No.4 Pharmaceutical Boosts Development of Modified Innovative Drugs
Per the agreement, the two parties will jointly develop a Class 2.2 antispasmodic medicine for children and a Class 2.3 therapeutic drug for chronic obstructive pulmonary disease (COPD). Both are modified new chemical drugs designed to address unmet clinical medical demands.
Jun 05,2026
SSY Golden Gate Shines at Overseas Pharmaceutical Raw Material Exhibition
We secured multiple prospective cooperation deals after exhibiting core API and finished drug lines.The exhibition effectively expanded our global sales channels and built new long-term partnership intentions.
Jun 05,2026
Golden Gate Pharmaceutical Debuts Full-range Medical Packaging Materials at Global Healthcare Fair
Our integrated medicine & packaging solution gained high recognition from global formulation producers.
Jun 05,2026
In-depth Global Business Negotiations Achieved at International Medical Device Exhibition
Face-to-face onsite negotiation greatly speeds up our market expansion across emerging regions.
Jun 05,2026
New Product Release & Compliance Sharing at Regional Pharmaceutical Summit
Compliance sharing and new product launch bring abundant high-intent overseas customers.
Get In Touch
Leave your email to receive our latest product catalog, pricing updates and company news.
Contact Us
Contact Person: Henry
Whatsapp: +8613831178092
Email: liyx@sjzsiyao.com
No.10，Fengchan Road，E & T Development Zone, Shijiazhuang city, Hebei Province, China
-
-
E-mail
-
WhatsApp
-
WhatsApp